Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Business Wire•29/09/2026•06:30 ET
0
Key Highlights
- ➤70% lower CLABSI hazard for Teleflex (TFX) Arrowg+ard™ CVCs (HR 0.297; p=0.003)
- ➤1,750 critically ill patients studied across six hospitals in four countries
- ➤18.4% mortality with CH/SSD CVCs versus 28.3% with plain CVCs
- ➤Zero CLABSI events during 0-5 catheter days with CH/SSD CVCs versus 13 plain-CVC events
Expert Statements
Jake Newman, President and General Manager, Global Vascular and Emergency Medicine, Teleflex
“At Teleflex, we are committed to investing in and generating clinical evidence necessary to support informed healthcare decision-making. These findings strengthen the clinical evidence supporting Arrowg+ard™ Technology and reinforce our commitment to developing innovations that help clinicians and improve patient outcomes.”
Dr. Amy Bardin, Vice President, Clinical and Medical Affairs, Teleflex
“Preventing healthcare-associated infections remains a critical priority for clinicians and healthcare systems worldwide. Clinicians rely on high-quality clinical evidence to inform infection prevention strategies. This multinational study adds important clinical evidence supporting Arrowg+ard™ Technology and demonstrates a statistically significant association with reduced CLABSI hazard among critically ill patients”
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Peer-reviewed publication in the American Journal of Infection Control demonstrates the use of CVCs protected with Arrowg+ard™ Technology are associated with a statistically significant and clinically meaningful reduction in the hazard of CLABSI compared with plain CVCs(1).
Get started
Create a free account to read the full story.